ArticlePloS one2026
Trends in the burden of gastroesophageal reflux disease in China and Global from 1990 to 2021 and predictive analysis for 2040.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study analyzed the temporal trends in the age- and gender-specific disease burden of gastroesophageal reflux disease (GERD) in China from 1990 to 2021, comparing its incidence, prevalence, and disability-adjusted life years (DALYs) with global estimates.
methodsData were extracted from the Global Burden of Disease (GBD) database 1990-2021. The Joinpoint regression model was used to quantify trends via annual average percentage change (AAPC) and 95% confidence intervals. Multidimensional comparisons were conducted by age, gender, and time.
resultsFrom 1990 to 2021, China exhibited declining trends in age-standardized incidence, prevalence, and DALYs rates for GERD, in contrast to increasing trends globally. Disease burden was higher among females and increased with age, with the middle-aged and elderly experiencing the greatest rise. Projections indicate a continued increase in GERD burden in China by 2040.
conclusionDespite recent declines, GERD remains a significant public health challenge in China due to its large population and rapid aging. Targeted prevention and intervention strategies are urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.